HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hakcensack UMC 10R22

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Sponsor
TG Therapeutics

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer